alnylam pharmaceuticals glp-1 receptor agonist Trends in the Development of Agonists GLP-1 receptor agonists and next-generation

They dont track risks

A population-based study from Scandinavia provides some real-world information.

Engineering new ligands that specifically target multiple G protein-coupled receptors with desired activity profiles requires time-consuming and expensive cycles of design-make-test-analyse work

Medicaid coverage for GLP-1 drugs varies significantly by state and plan, with most programs requiring prior authorization and medical documentation of BMI, comorbidities, or failed weight loss attempts

The new class of weight-loss medications are hailed as game-changing wonder drugs, but just how safe and effective are they

An increasing number of patients treated with novel antidiabetic drugs, including glucagon-like-peptide-1 receptor agonists (GLP-1RA), dual glucose-dependent insulinotropic polypeptide receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors, are presenting in the perioperative...